AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully
Pros
  • A unique product (Zeneo) protected by numerous long patents (>400, up to 2036).
  • The addressable market is almost “limitless” thanks to the large number of NTEs the group could consider (over 200 compared to the current 6 under developed).
  • The potential upside is huge for Crossject, which is to be considered a start-up company.
Cons
  • The group still has no products on the market.
  • Crossject’s development has sometimes been slowed by delays in the production/registration processes and the group’s communication is not optimal.
Updates
07/10/24 EPSWe have fine-tuned our forecasts for the ...
25/09/24 EarningsH1 24: no real surprise, but a glimpse of ...
17/07/24 TargetWe have substantially revisited our mode...
17/07/24 EPSOur EPS goes down with the downward r...
17/07/24 NAVOur NAV valuation, based on future reve...
17/07/24 DCFOur DCF valuation goes down due to the ...
05/06/24 Financing i...Success of the capital increase
02/05/24 Financing i...We welcome the securing of the group’s f...
03/04/24 EarningsPatience is a virtue… hopefully
28/02/24 Financing i...Securing the financing needs
08/02/24 StrategyNo news is not always good news...
06/01/24 LatestMarketing initiative in the US
03/01/24 Other newsA new distribution agreement in Northern...
28/09/23 Other newsH1 23: no surprises before the release of ...
27/03/23 EPSWe have updated our model after the rele...
23/03/23 EarningsFY22: not much to learn from the release
12/01/23 Financing i...Crossject has announced it has raised €1...
26/09/22 EPSWe have only changed our short-term est...
23/09/22 EarningsA rather reassuring H1 22
05/09/22 EPSWe have adjusted our numbers to the cur...
05/09/22 NAVWe have adjusted our numbers to the cur...
05/09/22 DCFWe have adjusted our numbers to the cur...
25/07/22 TargetDespite the fact we have quite significant...
25/07/22 EPSOur short-term EPS forecasts have little ...
25/07/22 NAVWe have reviewed our assumptions regar...
25/07/22 DCFDespite the fact we have changed our mi...
22/07/22 LatestThe update of our assumptions confirms ...
20/06/22 LatestA major breakthrough for Crossject
29/03/22 EarningsFY21: not very meaningful, as expected
17/12/21 Financing i...New financing
24/09/21 EarningsH1 21: unsurprising (as usual)
31/08/21 EPSWe have fine-tuned our numbers on the b...
18/08/21 EPSWe have only integrated the detailed num...
18/06/21 LatestAnother good piece of news for the group
17/06/21 LatestA licensing agreement for Zeneo Hydroco...
31/03/21 EarningsFY20 unsuprising; waiting for more
15/12/20 Financing i...A double bond issue
21/09/20 EarningsUpdate on the group's business
Target
Upside 285%
Price (€) 1.91
Market Cap (€M) 78.8
Perf. 1W: -8.17%
Perf. 1M: -2.05%
Perf. 3M: -14.7%
Perf Ytd: -61.2%
10 day relative perf. to stoxx600: -5.33%
20 day relative perf. to stoxx600: -8.26%